Hanmi Pharm Co Ltd
KRX:128940

Watchlist Manager
Hanmi Pharm Co Ltd Logo
Hanmi Pharm Co Ltd
KRX:128940
Watchlist
Price: 436 500 KRW -2.57% Market Closed
Market Cap: 5.6T KRW

Operating Margin
Hanmi Pharm Co Ltd

13.7%
Current
14%
Average
6.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
13.7%
=
Operating Profit
200.9B
/
Revenue
1.5T

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
KR
Hanmi Pharm Co Ltd
KRX:128940
5.5T KRW
14%
US
Eli Lilly and Co
NYSE:LLY
993.4B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
508.5B USD
27%
CH
Roche Holding AG
SIX:ROG
256.1B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
209.1B GBP
24%
CH
Novartis AG
SIX:NOVN
206.4B CHF
33%
US
Merck & Co Inc
NYSE:MRK
243.7B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
209B USD
11%
US
Pfizer Inc
NYSE:PFE
142.5B USD
29%
No Stocks Found

Hanmi Pharm Co Ltd
Glance View

Market Cap
5.5T KRW
Industry
Pharmaceuticals

Hanmi Pharm Co., Ltd. is a remarkable player in the pharmaceutical industry hailing from South Korea, a country renowned for its technological and medical advancements. The company's journey began in 1973, and it has since carved out a substantial niche within the pharma sector by focusing on innovative research and development. Hanmi Pharm has been particularly recognized for its strong pipeline in pharmaceuticals addressing diabetes, oncology, and autoimmune diseases. It leverages its cutting-edge proprietary technology platforms such as LAPSCOVERY, which is dedicated to creating long-acting biologics, and Quantum Project, focused on novel small molecule drugs. These platforms are pivotal to Hanmi's strategy, enabling it not only to excel in creating new drugs but also to foster partnerships and licensing deals on a global scale, which constitute a significant revenue stream for the company. Beyond innovation, Hanmi Pharm has diversified its business operations across various sectors of pharmaceuticals including finished goods, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products. The company's revenue model is multifaceted and robust; it generates income by selling its pharmaceuticals in domestic and international markets and taps into significant contract manufacturing opportunities. Additionally, Hanmi Pharm has managed to establish strategic alliances with global pharmaceutical giants, resulting in lucrative licensing agreements. These collaborations allow Hanmi to not only broaden its distribution channels but also enhance its R&D capabilities by synergizing with the technological prowess of its partners. Through these multifarious routes, Hanmi Pharm has built a complex, enduring, and well-oiled machine that propels its financial growth and sustains its competitive edge within the industry.

Intrinsic Value
349 720.35 KRW
Overvaluation 20%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
13.7%
=
Operating Profit
200.9B
/
Revenue
1.5T
What is the Operating Margin of Hanmi Pharm Co Ltd?

Based on Hanmi Pharm Co Ltd's most recent financial statements, the company has Operating Margin of 13.7%.

Back to Top